{"created":"2021-03-01T06:40:28.698911+00:00","id":34030,"links":{},"metadata":{"_buckets":{"deposit":"8360642d-3b34-4dc0-8f48-f586ed6e03dd"},"_deposit":{"id":"34030","owners":[],"pid":{"revision_id":0,"type":"depid","value":"34030"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00034030"},"item_6_alternative_title_1":{"attribute_name":"\u305d\u306e\u4ed6\u306e\u30bf\u30a4\u30c8\u30eb","attribute_value_mlt":[{"subitem_alternative_title":"\u65b0\u898fGSK-3\u03b2\u963b\u5bb3\u85ac\u3067\u3042\u308b9-ING-41\u306f\u8180\u80f1\u764c\u306b\u5bfe\u3057\u3066\u6297\u816b\u760d\u52b9\u679c\u3092\u767a\u63ee\u3059\u308b"}]},"item_6_date_granted_51":{"attribute_name":"\u5b66\u4f4d\u6388\u4e0e\u5e74\u6708\u65e5","attribute_value_mlt":[{"subitem_dategranted":"2020-03-23"}]},"item_6_degree_grantor_49":{"attribute_name":"\u5b66\u4f4d\u6388\u4e0e\u6a5f\u95a2","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_name":"\u65b0\u6f5f\u5927\u5b66"}]}]},"item_6_degree_name_48":{"attribute_name":"\u5b66\u4f4d\u540d","attribute_value_mlt":[{"subitem_degreename":"\u535a\u58eb(\u533b\u5b66)"}]},"item_6_description_4":{"attribute_name":"\u6284\u9332","attribute_value_mlt":[{"subitem_description":"Glycogen synthase kinase-3 beta (GSK-3\u03b2), a serine/threonine kinase, has been identifed as a potential therapeutic target in human bladder cancer. In the present study, we investigated the antitumor effect of a small molecule GSK-3\u03b2 inhibitor, 9-ING-41, currently in clinical studies in patients with advanced cancer, in bladder cancer cell lines. We found that treatment with 9-ING-41 leads to cell cycle arrest, autophagy and apoptosis in bladder cancer cells. The autophagy inhibitor chloroquine potentiated the antitumor effect of 9-ING-41 when tested in combination studies. Our fndings also demonstrate that9-ING-41 enhanced the growth inhibitory effects of gemcitabine or cisplatin when used in combination in bladder cancer cells. Finally, we found that 9-ING-41 sensitized bladder cancer cells to the cytotoxic effects of human immune effector cells. Our results provide a rationale for the inclusion of patients with advanced bladder cancer in clinical studies of 9-ING-41.","subitem_description_type":"Abstract"}]},"item_6_description_5":{"attribute_name":"\u5185\u5bb9\u8a18\u8ff0","attribute_value_mlt":[{"subitem_description":"Scientific Reports. 2019, 9, 19977.","subitem_description_type":"Other"}]},"item_6_description_53":{"attribute_name":"\u5b66\u4f4d\u8a18\u756a\u53f7","attribute_value_mlt":[{"subitem_description":"\u65b0\u5927\u9662\u535a(\u533b)\u7532\u7b2c939\u53f7","subitem_description_type":"Other"}]},"item_6_dissertation_number_52":{"attribute_name":"\u5b66\u4f4d\u6388\u4e0e\u756a\u53f7","attribute_value_mlt":[{"subitem_dissertationnumber":"13101\u7532\u7b2c4705\u53f7"}]},"item_6_full_name_3":{"attribute_name":"\u8457\u8005\u5225\u540d","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"178059","nameIdentifierScheme":"WEKO"}],"names":[{"name":"\u9ed2\u6728, \u5927\u751f"}]}]},"item_6_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"info:doi/10.1038/s41598-019-56461-4","subitem_relation_type_select":"DOI"}}]},"item_6_select_19":{"attribute_name":"\u8457\u8005\u7248\u30d5\u30e9\u30b0","attribute_value_mlt":[{"subitem_select_item":"ETD"}]},"item_creator":{"attribute_name":"\u8457\u8005","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kuroki, Hiroo"}],"nameIdentifiers":[{"nameIdentifier":"178058","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"\u30d5\u30a1\u30a4\u30eb\u60c5\u5831","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-08-31"}],"displaytype":"detail","filename":"r1nmk939.pdf","filesize":[{"value":"2.7 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"\u672c\u6587","url":"https://niigata-u.repo.nii.ac.jp/record/34030/files/r1nmk939.pdf"},"version_id":"3b451164-9069-4e4d-8765-1a4d6d9d1c26"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-08-31"}],"displaytype":"detail","filename":"r1nmk939_a.pdf","filesize":[{"value":"573.4 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"\u8981\u65e8","url":"https://niigata-u.repo.nii.ac.jp/record/34030/files/r1nmk939_a.pdf"},"version_id":"4df306ba-ec93-41b6-bf6d-0a295b4e0f48"}]},"item_language":{"attribute_name":"\u8a00\u8a9e","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"\u8cc7\u6e90\u30bf\u30a4\u30d7","attribute_value_mlt":[{"resourcetype":"thesis","resourceuri":"http://purl.org/coar/resource_type/c_46ec"}]},"item_title":"9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the efects of anticancer therapeutics in bladder cancer","item_titles":{"attribute_name":"\u30bf\u30a4\u30c8\u30eb","attribute_value_mlt":[{"subitem_title":"9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the efects of anticancer therapeutics in bladder cancer"}]},"item_type_id":"6","owner":"1","path":["453/455","471/561/562"],"pubdate":{"attribute_name":"\u516c\u958b\u65e5","attribute_value":"2020-08-31"},"publish_date":"2020-08-31","publish_status":"0","recid":"34030","relation_version_is_last":true,"title":["9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the efects of anticancer therapeutics in bladder cancer"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2021-03-01T07:53:42.792245+00:00"}